What if birth control wasn’t just a woman’s responsibility? For decades, options for men have stalled at two ends of the spectrum: a condom or a scalpel. One is inconsistent, the other nearly permanent. Meanwhile, female contraceptives have evolved into dozens of choices—from pills and patches to implants and IUDs—each with varying degrees of control, convenience, and side effects.
Now, a quiet shift is underway. A new male contraceptive called ADAM™ could hit the market as early as 2028. It’s not a pill, not hormonal, and not permanent. Instead, it’s a quick outpatient procedure that blocks sperm at the source for up to two years. Early trial data suggests it’s effective, safe, and might finally fill a long-standing gap in reproductive health.
So, how does it work—and could it actually change the game for contraception? Let’s break it down.
What Is ADAM™ and How Does It Work?
ADAM™ is an experimental male contraceptive implant developed by the U.S.-based biotech company Contraline. It’s not a pill or a patch, and it doesn’t mess with hormones. Instead, it’s a soft, water-based gel that gets injected directly into the vas deferens—the duct that carries sperm from the testicles to the urethra. Once in place, the gel physically blocks sperm from mixing with semen during ejaculation.
The entire procedure takes less than 20 minutes and is done with a local anesthetic—no surgery, no scalpel. Unlike vasectomy, which involves cutting and sealing the vas deferens, ADAM™ creates a temporary blockage. This means men can potentially restore fertility once the gel dissolves or is removed through a minimally invasive process.
What sets ADAM™ apart is that it doesn’t interfere with sexual sensation or ejaculation. Everything feels and works the same—except for the sperm part. According to trial data, sperm count drops by more than 99.8% within the first month of implantation, which is on par with permanent vasectomy levels.
ADAM™ is also designed with reversibility in mind. The hydrogel is engineered to gradually break down over time, restoring the flow of sperm naturally. Contraline is also developing a protocol for early removal if someone wants to reverse the effect before the two-year mark.
Clinical Trial Results: What We Know So Far
So far, ADAM™ has shown strong early results in human trials. The first-in-human Phase 1 study, conducted in Australia, involved 25 male participants who received the hydrogel implant through a quick outpatient procedure. Among them, two participants have now reached the 24-month mark, maintaining a zero sperm count the entire time—an outcome known as azoospermia. That means no viable sperm in their semen for two full years.
Across all participants, the contraceptive effect appears consistent. Lab tests and home-based sperm analysis have confirmed significantly reduced sperm levels at 12, 15, 18, and 21 months after implantation. Within the first month, the hydrogel reduced motile sperm by 99.8% to 100%, a rate comparable to vasectomy.
Crucially, there have been no serious adverse events reported. Minor side effects, like temporary swelling or light bruising, were consistent with what’s expected from similar procedures such as no-scalpel vasectomy. These effects resolved on their own within days.
While the trial was not designed to confirm reversibility in humans, data from animal studies suggest the hydrogel safely breaks down over time. Earlier human participants who received lower doses of the gel showed shorter periods of contraceptive effectiveness, which supports the idea that the product’s duration is dose-dependent—a useful trait for tailoring contraception to individual needs.
The study’s next step is Phase 2, which will involve 30 to 50 participants and focus more directly on testing reversibility, safety over time, and refining dosage. That trial is set to begin later this year, again in Australia, and the company is working with the FDA to begin trials in the U.S. as well.
Why This Could Be a Game-Changer
The demand for male contraception has been loud for years, but innovation has lagged far behind. Men have essentially had two options: condoms, which are convenient but prone to failure, and vasectomy, which is reliable but often permanent. That’s it. While women have had access to a wide variety of hormonal and non-hormonal birth control methods, the burden of preventing pregnancy has largely been theirs to carry.
ADAM™ could shift that balance.
Contraline’s market research shows that many men are actively looking for more control over their reproductive choices. In fact, the company reported a waitlist of over 15,000 men who signed up for updates—without any paid marketing. A separate survey showed that 35% of men preferred a contraceptive that lasts 1–2 years, and many favored a method that doesn’t require daily pills or hormonal side effects.
The timing is also significant. Since the overturning of Roe v. Wade, vasectomy rates among younger men have reportedly increased, suggesting a growing awareness and willingness among men to take charge of birth control. But not everyone is ready for a permanent solution. ADAM™ offers something different: long-lasting, non-permanent, and non-hormonal contraception.
Experts in reproductive health also see the potential. Professor Richard Anderson of the University of Edinburgh called the early data “impressive,” noting that ADAM™ joins a small but growing list of promising male contraceptive technologies. Unlike hormonal pills that can interfere with testosterone or affect mood and libido, ADAM™ works mechanically—blocking sperm without touching the rest of the body’s systems.
If ADAM™ clears the next phases of clinical testing and proves to be reliably reversible, it could mark the first major shift in male birth control in over 60 years. That would not only give men more autonomy, but also ease the contraceptive burden on women—and that’s something couples across the board have been asking for.
What About Reversibility and Long-Term Effects?
Reversibility is the make-or-break factor for any male contraceptive that isn’t permanent. It’s also the biggest question still hanging over ADAM™.
While animal studies have shown that the hydrogel breaks down predictably over time, human data on reversibility is still limited. The two men who have reached the 24-month mark in the current trial are still under observation, and the gel remains in place. That means we don’t yet have confirmation of how reliably fertility returns once the gel dissolves or is removed.
Contraline is aware this is a top concern. As CEO Kevin Eisenfrats put it, “Reversibility is sort of everything—it’s the difference between this product being a vasectomy alternative and it being the IUD for men.” The company is planning to address this head-on in its upcoming Phase 2 trial, which will test both natural biodegradation of the gel and early removal using a simple follow-up procedure.
So far, the hydrogel appears to be biocompatible—meaning it doesn’t trigger inflammation, scarring, or damage to surrounding tissue. That’s critical for maintaining the possibility of reversal. Still, experts are urging caution. Dr. Jon Oatley of Washington State University noted that we don’t yet understand the long-term effects of blocking the vas deferens. Prolonged obstruction, even if non-permanent, could theoretically cause pressure buildup or structural changes in the reproductive tract over time.
Another unknown is whether sperm production itself stays fully functional during the blockage. While ADAM™ prevents sperm from entering semen, it’s not yet clear how the body adjusts internally over longer durations. If the gel remains in place for multiple years, will sperm production bounce back immediately? Will there be a decline in sperm quality or fertility potential afterward? These are questions that only longer-term human studies can answer.
Practical Insights for Men (and Couples)
If ADAM™ becomes widely available, it could give men a much-needed option that fits between short-term and permanent birth control. But who might it actually be right for—and what should men and their partners consider?
1. Ideal for men who want long-term, non-permanent birth control.
ADAM™ is designed to last around two years, making it appealing for men who want a break from condoms but aren’t ready (or willing) to commit to a vasectomy. This includes men in long-term relationships who aren’t currently planning to have kids but want that door open in the future.
2. No daily maintenance.
Like IUDs or implants used by women, once ADAM™ is in, you don’t have to think about it. There’s no pill to remember, no routine to follow, and no supply to keep stocked. It’s a “set it and forget it” approach that’s especially useful for couples who want low-maintenance contraception without relying solely on female birth control.
3. Doesn’t interfere with sex.
One of ADAM™’s biggest selling points is that it doesn’t affect sexual function. Ejaculation feels the same. There’s no hormone disruption, no reported impact on libido, and no visible difference. For many men, this could make it a more appealing option than hormonal contraceptives currently in development.
4. Reproductive control is shared—not shifted.
In many relationships, the responsibility of birth control has fallen mostly on women. ADAM™ opens up an alternative that lets men take on a more active role. For couples, this could mean more equitable family planning and better communication about who’s taking which precautions, when, and why.
5. It’s not ready yet—but you can prepare.
While ADAM™ won’t be available until at least 2028 (pending trial results and regulatory approval), it’s worth thinking ahead. Men who are curious about alternatives to condoms or vasectomy can start by talking to their partners and healthcare providers about long-term planning and preferences.
It’s also important to understand that, like all forms of birth control, ADAM™ won’t be one-size-fits-all. Some men may prefer the idea of a pill or topical gel, both of which are also in development. Others may not want a procedure at all—and that’s fine. The real value is in having more choices.
A New Era in Birth Control?
ADAM™ isn’t just another experimental contraceptive—it may finally be the male birth control option that sticks. Early trial results show it can block sperm for up to two years with no major side effects, and the procedure is quick, non-surgical, and hormone-free. It’s a practical middle ground between condoms and vasectomy, tailored to what many men say they actually want: something long-lasting but reversible.
Still, a lot rides on what comes next. The Phase 2 trial will need to prove that reversibility works reliably in humans and that there are no long-term complications from blocking the vas deferens. Without that data, ADAM™ remains promising—but incomplete.
What’s clear is that the demand is real. Tens of thousands of men have already expressed interest, and cultural attitudes around contraception are shifting. More men are willing to take on the responsibility, and more couples want shared control over birth prevention.
If ADAM™ clears the final hurdles, we could be looking at the first true breakthrough in male contraception in over half a century. Not just another study, but a real product with real impact—possibly available as early as 2028.
That timeline isn’t guaranteed, but the momentum is. After decades of stalled progress, male birth control might finally be moving forward.
